SCHEMBL125175

SCHEMBL125175

CCN1CC=C(CC#N)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
ALOX15 P16050 2/20 0.35
LMNA P02545 2/20 0.35
DRD2 P14416 2/20 0.35
DRD4 P21917 2/20 0.35
HTR6 P50406 2/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
PTK2B Q14289 1/20 0.32
ESR2 Q92731 1/20 0.32
HSD17B10 Q99714 1/20 0.32
SETD7 Q8WTS6 1/20 0.32
HRH3 Q9Y5N1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13262133 0.79 KDM4E (0.40) KDM4EALOX15LMNADRD2DRD4
SCHEMBL14354546 0.78 QDPR (0.37)
SCHEMBL7833304 0.76 ALOX15 (0.38) KDM4EALOX15LMNADRD2DRD4
SCHEMBL9133084 0.74 KDM4E (0.37) KDM4EALOX15LMNADRD2DRD4
SCHEMBL24975288 0.73 KDM4E (0.36) KDM4EALOX15LMNADRD2DRD4
SCHEMBL12233782 0.73 KDM4E (0.36) KDM4EALOX15LMNADRD2DRD4
SCHEMBL9129212 0.71 KDM4E (0.35) KDM4EALOX15LMNADRD2DRD4
SCHEMBL1762873 0.70 HSD11B1 (0.37) KDM4EALOX15LMNADRD2DRD4
SCHEMBL1687842 0.70 DRD2 (0.33) DRD2
SCHEMBL1772764 0.69 LMNA (0.37) KDM4ELMNADRD2DRD4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103443076-A Indol-2-one derivatives disubstituted in position 3, their preparation and their therapeutic application SANOFI AVENTIS 2013-12-11 CN disclosed
US-8202871-B2 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-06-19 US disclosed
EP-2188253-B1 Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2012-03-07 EP disclosed
US-20100210662-A1 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-08-19 US disclosed
EP-2188253-A2 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-05-26 EP disclosed
WO-2009056707-A2 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210662-A1 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF IDO2, IDO1, TPH2 KDM4E 2168/4885ALOX15 3165/4885LMNA 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.